Abner Antonio Murray: Zongertinib delivers major hope for pretreated HER2-mutant NSCLC
Apr 30, 2025, 05:41

Abner Antonio Murray: Zongertinib delivers major hope for pretreated HER2-mutant NSCLC

Abner Antonio Murray, Hematology-Oncology Fellow at UNC Hematology-Oncology Fellowship, shared a post on X:

“Breaking at AACR25:
Zongertinib delivers major hope for pretreated HER2-mutant NSCLC.
71% ORR and 96% DCR in patients with TKD HER2 mutations (Cohort 1)
Median PFS 12.4 months; DoR 14.1 months durable benefit
Manageable safety: low ≥G3 AEs, no drug-related ILD
48% ORR even after HER2-directed ADC resistance (T-DXd)
Clinical benefit seen even in patients with brain metastases
FDA Priority Review underway for advanced/metastatic HER2+ NSCLC
Beamon LUNG-2 Phase 3 trial enrolling for 1L therapy

Zongertinib could redefine treatment for this high-need population.”

Abner Antonio Murray: Zongertinib delivers major hope for pretreated HER2-mutant NSCLC Abner Antonio Murray: Zongertinib delivers major hope for pretreated HER2-mutant NSCLC